| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
48,440,000 |
| Market
Cap: |
754.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$10.35 - $19.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.1 |
| Insider 6 Months : 8.1 |
| Insider 3/6 Months : 16.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. Co.'s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to improve immunogenicity and stability of the VLPs in solution. VLPs are self-assembling structures that mimic the certain and repetitive geometric features that characterize the surface of a live virus. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,100 |
10,100 |
10,100 |
10,100 |
| Total Buy Value |
$149,550 |
$149,550 |
$149,550 |
$149,550 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
2 |
2 |
| Total Shares Sold |
78,898 |
152,870 |
157,870 |
157,870 |
| Total Sell Value |
$986,502,618 |
$987,594,204 |
$987,659,204 |
$987,659,204 |
| Total People Sold |
1 |
4 |
4 |
4 |
| Total Sell Transactions |
15 |
24 |
25 |
25 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Borkowski Astrid |
Chief Medical Officer |
• – – |
2024-02-08 |
4 |
S |
$14.93 |
$58,726 |
D/D |
(3,933) |
161,260 |
|
-0% |
|
| Borkowski Astrid |
Chief Medical Officer |
• – – |
2023-12-15 |
4 |
S |
$15.50 |
$155,000 |
D/D |
(10,000) |
165,193 |
|
9% |
|
| Borkowski Astrid |
Chief Medical Officer |
• – – |
2023-12-04 |
4 |
S |
$14.50 |
$145,000 |
D/D |
(10,000) |
175,193 |
|
5% |
|
| Borkowski Astrid |
Chief Medical Officer |
• – – |
2023-12-01 |
4 |
S |
$14.20 |
$142,000 |
D/D |
(10,000) |
185,193 |
|
-4% |
|
| Borkowski Astrid |
Chief Medical Officer |
• – – |
2023-11-17 |
4 |
S |
$14.00 |
$140,000 |
D/D |
(10,000) |
195,193 |
|
-17% |
|
| Borkowski Astrid |
Chief Medical Officer |
• – – |
2023-11-08 |
4 |
S |
$13.00 |
$65,000 |
D/D |
(5,000) |
205,193 |
|
-24% |
|
| Borkowski Astrid |
Chief Medical Officer |
• – – |
2023-06-21 |
4 |
D |
$16.11 |
$161,100 |
D/D |
(10,000) |
210,193 |
|
- |
|
| Kohli Aditya |
Chief Operating Officer |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
85,466 |
821,744 |
|
- |
|
| Hershberg Robert |
President and CEO |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
187,966 |
965,428 |
|
- |
|
| Maltbie Shane |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
43,333 |
44,232 |
|
- |
|
| Borkowski Astrid |
Chief Medical Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
51,333 |
219,774 |
|
- |
|
| Maltbie Shane |
Chief Financial OfficerOfficer |
• – – |
2023-01-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
899 |
|
-3% |
|
| Takeda Vaccines, Inc. |
10% Owner |
– – • |
2022-11-30 |
4 |
OE |
$0.00 |
$0 |
I/I |
5,883,500 |
6,724,000 |
|
- |
|
| Takeda Vaccines, Inc. |
10% Owner |
– – • |
2022-05-03 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
840,500 |
|
- |
|
| Heron Patrick J |
Director |
– • • |
2022-05-03 |
4 |
B |
$17.00 |
$30,000,002 |
D/D |
1,764,706 |
8,535,337 |
3.92 |
9% |
|
| Heron Patrick J |
Director |
– • • |
2022-05-03 |
4 |
OE |
$13.60 |
$37,212,782 |
D/D |
2,736,234 |
6,770,631 |
|
- |
|
| Takeda Vaccines, Inc. |
10% Owner |
– – • |
2022-04-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
500,000 |
|
- |
|
| Kohli Aditya |
Chief Operating OfficerOfficer |
• • – |
2022-04-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
736,278 |
|
- |
|
| Gerberding Julie L. |
Director |
– • – |
2022-04-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
42,025 |
|
- |
|
| Hilleman Jeryl L |
Director |
– • – |
2022-04-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
42,025 |
|
- |
|
| Socks David A |
CFO & Chief Business OfficerOf |
• – – |
2022-04-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
769,055 |
|
- |
|
| Silbermann Susan Michele |
Director |
– • – |
2022-04-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
42,025 |
|
- |
|
| Sepulveda Jaime |
Director |
– • – |
2022-04-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
42,025 |
|
- |
|
| Borkowski Astrid |
Chief Medical OfficerOfficer |
• – – |
2022-04-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
168,100 |
|
- |
|
49 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.47 (3.11%) 
